Langer-Giedion syndrome

Langer-Giedion Syndrome (LGS), also known as Trichorhinophalangeal Syndrome Type II (TRPS II), is a rare genetic disorder characterized by distinctive facial features, skeletal abnormalities, and the growth of noncancerous bone tumors called exostoses. This condition results from deletions or mutations in the EXT1 gene and, less commonly, the TRPS1 gene, located on chromosome 8. Langer-Giedion Syndrome is inherited in an autosomal dominant pattern, but many cases result from de novo mutations.

Clinical Features

Langer-Giedion Syndrome presents a unique set of clinical features, including:

• Facial Features: Individuals with LGS often have a distinctive facial appearance with a long, narrow face, a bulbous nose, deep-set eyes, and large, protruding ears.
• Skeletal Abnormalities: Common skeletal issues include cone-shaped epiphyses at the phalanges, short stature, and multiple exostoses that can lead to pain and deformity.
• Intellectual Disability: Mild to moderate intellectual disability is common among individuals with LGS, although the severity can vary widely.
• Hair Anomalies: Sparse scalp hair, as well as abnormalities in the texture and growth of hair, are often observed.

Diagnosis

Diagnosis of Langer-Giedion Syndrome is primarily based on clinical observation and the presence of characteristic features. Genetic testing can confirm deletions or mutations in the EXT1 and TRPS1 genes, providing a definitive diagnosis. Imaging studies, such as X-rays, are used to identify skeletal abnormalities and the presence of exostoses.

Management and Treatment

There is no cure for Langer-Giedion Syndrome, and treatment focuses on managing symptoms and improving quality of life. Management strategies may include:

• Surgical Removal of Exostoses: Surgery may be necessary to remove painful or obstructive bone tumors.
• Orthopedic Interventions: Orthopedic surgery may be required to correct skeletal deformities and improve mobility.
• Educational Support: Individuals with intellectual disabilities may benefit from specialized educational programs and support services.
• Regular Monitoring: Regular follow-up with a multidisciplinary team is essential to monitor growth, development, and the emergence of new symptoms.

Prognosis

The prognosis for individuals with Langer-Giedion Syndrome varies depending on the severity of symptoms and the presence of complications. With appropriate management, most individuals can lead active and fulfilling lives. However, the presence of multiple exostoses can lead to significant morbidity.

Epidemiology

Langer-Giedion Syndrome is a rare disorder, with an estimated prevalence of 1 in 1,000,000 live births. It affects males and females equally.

History

Langer-Giedion Syndrome was first described in the medical literature in the 1960s by Langer and Giedion, who identified its distinct clinical and genetic features.

Langer-Giedion syndrome Resources
Latest articles Most recent articles Ongoing trials	Wikipedia